Literature DB >> 34537923

Astaxanthin Ameliorates Blood Pressure in Salt-Induced Prehypertensive Rats Through ROS/MAPK/NF-κB Pathways in the Hypothalamic Paraventricular Nucleus.

Hong-Li Gao1, Xiao-Jing Yu1, Yan Zhang1, Chen-Long Wang1, Yi-Ming Lei1, Jia-Yue Yu1, Dong-Miao Zong1, Kai-Li Liu1, Dong-Dong Zhang1, Ying Li1, Hua Tian1, Nian-Ping Zhang2, Yu-Ming Kang3.   

Abstract

Astaxanthin (AST) has a variety of biochemical effects, including anti-inflammatory, antioxidative, and antihypertensive functions. The aim of the present study was to determine whether AST ameliorates blood pressure in salt-induced prehypertensive rats by ROS/MAPK/NF-κB pathways in hypothalamic paraventricular nucleus.To explore the central effects of AST on the development of blood pressure, prehypertensive rats were induced by a high-salt diet (HS, 8% NaCl) and its control groups were treated with normal-salt diet (NS, 0.3% NaCl). The Dahl salt-sensitive (S) rats with HS diet for 6 weeks received AST or vehicle by gastric perfusion for 6 weeks. Compared to those with NS diet, rats with HS diet exhibited increased mean arterial pressure (MAP) and heart rate (HR). These increases were associated with higher plasma level of norepinephrine (NE), interleukin 1β (IL-1β), and interleukin 6 (IL-6); elevated PVN level of reactive oxygen species (ROS), NOX2, and NOX4, that of IL-1β, IL-6, monocyte chemotactic protein 1 (MCP-1), tyrosine hydroxylase (TH), phosphorylation extracellular-signal-regulated kinase (p-ERK1/2), phosphorylation Jun N-terminal kinases (p-JNK), nuclear factor-kappa B (NF-κB) activity; and lower levels of IL-10, superoxide dismutase (SOD), and catalase (CAT) in the PVN. In addition, our data demonstrated that chronic AST treatment ameliorated these changes in the HS but not NS diet rats. These data suggested that AST could alleviate prehypertensive response in HS-induced prehypertension through ROS/MAPK/NF-κB pathways in the PVN.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Astaxanthin; Hypothalamic paraventricular nucleus; Inflammatory cytokines; MAPK; Oxidative stress; Prehypertension

Mesh:

Substances:

Year:  2021        PMID: 34537923     DOI: 10.1007/s12012-021-09695-6

Source DB:  PubMed          Journal:  Cardiovasc Toxicol        ISSN: 1530-7905            Impact factor:   3.231


  33 in total

Review 1.  Dietary contributors to hypertension in adults reviewed.

Authors:  D M A McCartney; D G Byrne; M J Turner
Journal:  Ir J Med Sci       Date:  2014-08-24       Impact factor: 1.568

Review 2.  Evidence for a critical role of the sympathetic nervous system in hypertension.

Authors:  Guido Grassi; Venkata S Ram
Journal:  J Am Soc Hypertens       Date:  2016-03-04

3.  Angiotensin II-induced hypertension is modulated by nuclear factor-κBin the paraventricular nucleus.

Authors:  Jeffrey P Cardinale; Srinivas Sriramula; Nithya Mariappan; Deepmala Agarwal; Joseph Francis
Journal:  Hypertension       Date:  2011-11-21       Impact factor: 10.190

4.  Inflammatory cytokines in paraventricular nucleus modulate sympathetic activity and cardiac sympathetic afferent reflex in rats.

Authors:  Z Shi; X-B Gan; Z-D Fan; F Zhang; Y-B Zhou; X-Y Gao; W De; G-Q Zhu
Journal:  Acta Physiol (Oxf)       Date:  2011-05-27       Impact factor: 6.311

Review 5.  Hypertension in the developing world: challenges and opportunities.

Authors:  Bharati V Mittal; Ajay K Singh
Journal:  Am J Kidney Dis       Date:  2009-12-05       Impact factor: 8.860

6.  Blood pressure variability, impaired autonomic function and vascular senescence in aged spontaneously hypertensive rats are ameliorated by angiotensin blockade.

Authors:  Daisuke Sueta; Nobutaka Koibuchi; Yu Hasegawa; Kensuke Toyama; Ken Uekawa; Tetsuji Katayama; MingJie Ma; Takashi Nakagawa; Hidefumi Waki; Masanobu Maeda; Hisao Ogawa; Shokei Kim-Mitsuyama
Journal:  Atherosclerosis       Date:  2014-06-26       Impact factor: 5.162

7.  Calcitriol ameliorated autonomic dysfunction and hypertension by down-regulating inflammation and oxidative stress in the paraventricular nucleus of SHR.

Authors:  Meng-Lu Xu; Xiao-Jing Yu; Jian-Qiang Zhao; Yan Du; Wen-Jie Xia; Qing Su; Meng-Meng Du; Qing Yang; Jie Qi; Ying Li; Shao-Wen Zhou; Guo-Qing Zhu; Hong-Bao Li; Yu-Ming Kang
Journal:  Toxicol Appl Pharmacol       Date:  2020-03-05       Impact factor: 4.219

8.  Brain nuclear factor-kappa B activation contributes to neurohumoral excitation in angiotensin II-induced hypertension.

Authors:  Yu-Ming Kang; Ying Ma; Jin-Ping Zheng; Carrie Elks; Srinivas Sriramula; Zhi-Ming Yang; Joseph Francis
Journal:  Cardiovasc Res       Date:  2009-02-25       Impact factor: 10.787

9.  Exercise training rescues the electrical activity of liver-projecting DMNV neurones in response to oxytocin in spontaneously hypertensive rats.

Authors:  Karoline Martins Dos Santos; Davi José de Almeida Moraes; Melina Pires da Silva; Vagner Roberto Antunes
Journal:  J Neuroendocrinol       Date:  2021-05-04       Impact factor: 3.627

Review 10.  Astaxanthin: sources, extraction, stability, biological activities and its commercial applications--a review.

Authors:  Ranga Rao Ambati; Siew Moi Phang; Sarada Ravi; Ravishankar Gokare Aswathanarayana
Journal:  Mar Drugs       Date:  2014-01-07       Impact factor: 5.118

View more
  2 in total

1.  Resveratrol in the Hypothalamic Paraventricular Nucleus Attenuates Hypertension by Regulation of ROS and Neurotransmitters.

Authors:  Jie Qi; Li-Yan Fu; Kai-Li Liu; Rui-Juan Li; Jin-An Qiao; Xiao-Jing Yu; Jia-Yue Yu; Ying Li; Zhi-Peng Feng; Qiu-Yue Yi; Hong Jia; Hong-Li Gao; Hong Tan; Yu-Ming Kang
Journal:  Nutrients       Date:  2022-10-07       Impact factor: 6.706

2.  Exercise Training Attenuates Hypertension via Suppressing ROS/MAPK/NF-κB/AT-1R Pathway in the Hypothalamic Paraventricular Nucleus.

Authors:  Jie Qi; Rui-Juan Li; Li-Yan Fu; Kai-Li Liu; Jin-An Qiao; Yu Yang; Xiao-Jing Yu; Jia-Yue Yu; Ying Li; Hong Tan; Yu-Ming Kang
Journal:  Nutrients       Date:  2022-09-24       Impact factor: 6.706

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.